Non-small cell lung cancer survivin bcl 2 and bax protein and multidrug resistance gene expression and their correlation.doc

 PAGE \* MERGEFORMAT 18 Non-small cell lung cancer survivin bcl 2 and bax protein and multidrug resistance gene expression and their correlation 【Abstract】 Objective To detect non-small cell lung cancer (NSCLC) in the apoptotic protein survivin, bcl  2, bax and multidrug resistance related gene expression MDR1mRNA and MRPmRNA to explore their mutual relations and their significance. Methods 113 cases of NSCLC cases, using in situ hybridization detection of MDR1 and MRP gene mRNA expression, SP immunohistochemical detection of survivin, bcl  2, bax protein expression. Results 113 patients with NSCLC in, MDR1mRNA, MRPmRNA and survivin, bcl  2, bax protein in the detection rates were 51.3%, 80.5%, 79.6%, 59.3%, 54.9%. survivin and bax expression and the degree of tumor differentiation (P lt;0.05), bcl  2 expression and tumor histological type related (P lt;0.01). MDR1mRNA and MRPmRNA (P lt;0.01), survivin and MDR1mRNA (P lt;0.05), bcl  2 and MRPmRNA (P lt;0.05) correlation between the expression. Conclusion inhibitor of apoptosis protein survivin was highly expressed and bcl  2 over-expression may lead to drug-resistant NSCLC primary important factor in detecting survivin, and bcl  2 for clinical reversal of multidrug resistance of NSCLC has guiding significance. Keywords: multi-drug resistant lung cancer cell apoptosis in situ hybridization Immunohistochemistry 0 Introduction Multi-drug resistance (multidrug resistance, MDR) is the impact of non-small cell lung cancer (non  small cell lung cancer, NSCLC) the main effect of chemotherapy. A large number of studies have shown that multi-drug resistance mechanism is the role of multi-factor, multi-complex process of genetic modification. In recent years, in addition to the classic drug-resistant channels, inhibitor of apoptosis and multidrug resistance in the relationship between the more and more attention. This study selected 113 patients with untreated NSCLC patients, using in